GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
Links shared publicly online about this topic.
- 418total visits
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
gsk.com —
View full resource at gsk.com
Tags: Cancer, Prostate Cancer, Prostate, Benign Prostatic Hypertrophy Medication, Men's Health, Avodart, GlaxoSmithKline
Most Recently Shared on March 27, 2011 at 5:53 pm By:
GSK statement on Avodartâ„¢ (dutasteride) for prostate cancer risk ... http://bit.ly/go4aNR
Also Shared By:
GSK Statement on University of East Anglia Study Examining Health Impacts of Anticholinergic Medicines for Over 65s - Drugs.com MedNews
drugs.com — “Issued Friday 24 June 2011, London UK Research led by the University of East Anglia has been published in the Journal of the American Geriatrics Societyi examin” View full resource at drugs.com
Most Recently Shared on June 24, 2011 at 4:14 pm By:
Drugs and Devices OW OW Health
GSK Statement on University of East Anglia Study Examining Health Impacts of Anticholinergic Medicines for... http://bit.ly/l04JWe #drug
GSK withdraws applications for Avodart | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on March 25, 2011 at 4:58 pm By:
Pharmafocus Health News and Pharma
GSK withdraws applications for Avodart http://goo.gl/fb/avTCr
GlaxoSmithKline drops Avodart for prostate cancer risk reduction - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer. The company will withdraw applications from regulatory review where procedures are on” View full resource at thepharmaletter.com
Most Recently Shared on March 24, 2011 at 5:35 pm By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction http://bit.ly/gRCa25
Article > GSK pulls back filings for Avodart in prostate cancer
pharmatimes.com — “Article > GSK pulls back filings for Avodart in prostate cancer” View full resource at pharmatimes.com
Most Recently Shared on March 24, 2011 at 1:58 pm By:
GSK pulls back filings for Avodart in prostate cancer http://bit.ly/hRTVmF
GSK scraps plans to market prostate-cancer drug | The Associated Press | News | Washington Examiner
washingtonexaminer.com — “Drug giant GlaxoSmithKline PLC says it will no longer pursue global regulatory approval to market its Avodart drug to treat prostate cancer following negative feedback from American and Swedish regulators. Avodart is approved in more than 90 countries to treat an enlarged prostate.” View full resource at washingtonexaminer.com
Most Recently Shared on March 23, 2011 at 11:47 pm By:
GSK scraps plans to market prostate-cancer drug | The Associated ... http://bit.ly/eyOgBn
GSK scraps plans to market prostate-cancer drug
health.yahoo.net — “Drug giant GlaxoSmithKline PLC says it will no longer pursue global regulatory approval to market its Avodart drug to treat prostate cancer following negative feedback from American and Swedish regulators.” View full resource at health.yahoo.net
Most Recently Shared on March 23, 2011 at 4:40 pm By:
GSK scraps plans to market prostate-cancer drug http://bit.ly/hQd6cL
PharmaLive: GSK Receives FDA Complete Response Letter for Avodart for Prostate Cancer Risk Reduction Supplemental Indication
pharmalive.com — “PharmaLive: GSK Receives FDA Complete Response Letter for Avodart for Prostate Cancer Risk Reduction Supplemental Indication” View full resource at pharmalive.com
Most Recently Shared on January 27, 2011 at 10:24 pm By:
PharmaLive Pharma and Health News
Daily Advantage - FDA Nixes Avodart sNDA for Now - http://tinyurl.com/496xkub
FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk
news-medical.net — “GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).” View full resource at news-medical.net
Most Recently Shared on January 27, 2011 at 8:46 am By:
Prostate Cancer: FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk: Gla... http://bit.ly/gsJ8Y3
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction
medicalnewstoday.com — “GlaxoSmithKline (NYSE: GSK) announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (s” View full resource at medicalnewstoday.com
Most Recently Shared on December 2, 2010 at 3:37 pm By:
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction GlaxoSmithKline (NYSE: GSK) announced the.. http://dld.bz/8Wrf
Federal prosecutors indict former GSK vice president with obstruction of probe - News - Regulatory Affairs
regulatoryaffairs.pharmaceutical-business-review.com — “The US Department of Justice has charged Lauren Stevens, former vice president and associate general counsel of British drug manufacturer GlaxoSmithKline (GSK), with obstruction and making false statements during a USFDA investigation into unapproved uses of its antidepressant Wellbutrin for weight loss.” View full resource at regulatoryaffairs.pharmaceutical-business-review.com
Most Recently Shared on November 11, 2010 at 9:28 am By:
Jack Friday - PharmaGossip Health Blog
RT @Pharma_BR: Federal prosecutors indict former GSK vice president with obstruction of probe: http://bit.ly/cwYTXO #GSK
Glaxo Admits Mistakes With Paid Medical Journal Supplement - WSJ.com
online.wsj.com — “Glaxo Admits Mistakes With Paid Medical Journal Supplement - WSJ.com” View full resource at online.wsj.com
Most Recently Shared on July 26, 2010 at 3:27 pm By:
Ivan Oransky Doctor and Health Communicator
RT @GCPworks: Glaxo Admits Mistakes With Paid Medical Journal Supplement #Avodart #GSK http://bit.ly/bFN5Cf
Statement On FDA Placing Hold On TIDE Safety Trial
medicalnewstoday.com — “The U.S. Food and Drug Administration (FDA) informed GlaxoSmithKline (GSK), the manufacturer of rosiglitazone (Avandia), that the postmarketing safety trial known as TIDE has been placed on partia” View full resource at medicalnewstoday.com
Most Recently Shared on July 23, 2010 at 3:17 pm By:
Scott Strumello Patient Expert
Statement On FDA Placing Hold On Avandia TIDE Safety Trial http://bit.ly/aWToZ9
Statement on FDA Placing Hold on TIDE Safety Trial
endo-society.org — “The U.S. Food and Drug Administration (FDA) today informed GlaxoSmithKline (GSK), the manufacturer of rosiglitazone (Avandia), that the postmarketing safety trial known as TIDE has been placed on partial clinical hold...” View full resource at endo-society.org
Most Recently Shared on July 23, 2010 at 1:04 pm By:
TheEndocrineSociety Medical Society
Statement on FDA Placing Hold on TIDE Safety Trial http://tinyurl.com/28pxacp
GlaxoSmithKline statement in response to FDA announcement on TIDE trial
us.gsk.com — “GlaxoSmithKline statement in response to FDA announcement on TIDE trial” View full resource at us.gsk.com
Most Recently Shared on July 21, 2010 at 6:07 pm By:
eyeonfda Pharma and Health Lawyer
GSK statement in response to FDA announcement on TIDE trial http://ow.ly/2eDPH
Advertisement
eyeonfda
@eyeonfda
GSK statement in response to FDA announcement on TIDE trial http://ow.ly/2eDPH
1 year ago...